At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 125 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin and Glimepiride for Diabetes Mellitus, Type 2. Completed, enrolled 125 participants across 14 sites.
Detailed Summary
To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJan 2016
Primary CompletionJan 2018
TodayJul 2026
First PostedOct 1, 2015
Enrollment StartJan 5, 2016
Primary CompletionJan 15, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago
Interventions
Dapagliflozindrug
Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
Glimepiridedrug
Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment